研飞客户端支持数万种期刊查询，助你在阅读和写作中随时了解期刊动态
Statistics in Biopharmaceutical Research
| 短名 | Stat. Biopharm. Res. |
| Journal Impact | 1.62 |
| 国际分区 | STATISTICS & PROBABILITY(Q2) |
| 期刊索引 | SCI Q2中科院 4 区 |
| ISSN | 1946-6315 |
| h-index | 25 |
| 国内分区 | 医学(4区)医学数学与计算生物学(3区)医学统计学与概率论(4区) |
《Statistics in Biopharmaceutical Research》期刊专注于生物制药行业的研究，发表满足研究人员和应用统计学家需求的文章。我们欢迎来自医学院、兽医学院、公共卫生学院和药学院的学术生物统计学家，以及在监管机构（如美国食品和药物管理局及其国际对应机构）工作的统计学家和定量分析师。此外，我们也鼓励有兴趣将本期刊中介绍的方法应用于自身领域的统计学家，以及对生物制药问题中的统计方法感兴趣的非统计学家投稿。
期刊主页投稿网址阅读文献时，研飞即可帮你快速了解期刊，查询影响因子与分区，智能高亮期刊预警！
| 涉及主题 | 数学医学统计计算机科学经济生物内科学计量经济学病理生物信息学机器学习物理临床试验人工智能心理学 |
| 出版信息 | 出版商: Taylor and Francis Ltd.，出版周期: Quarterly，期刊类型: journal |
| 基本数据 | 创刊年份: 2011，原创研究文献占比: 98.00%，自引率:26.70%， Gold OA占比: 14.02% |
| 平均审稿周期 | 期刊官网数据：平均Submission to first decision: 65 days; Submission to first post-review decision: 101 days; Acceptance to online publication: 48 days;网友分享经验：>12周，或约稿 |
| 平均录用比例 | 网友分享经验：41% |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
手工熬夜修改参考文献？研飞自动匹配期刊，一键轻松成稿，支持 Word/WPS
点击下方按钮，免费开启试用！
最新文章
A new centralized statistical monitoring method for detecting atypical distribution of qualitative variables in multicenter randomized controlled trials
2024-9-30
Non-inferiority testing on the accuracy of two qualitative microbiological methods on paired binary data
2024-9-20
A primer of quasi-exact tests for randomized clinical trials with binary endpoints
2024-9-10
A Basket Trial Design Based on Power Priors
2024-9-10
Two-stage Adaptive Enrichment Designs with Survival Outcomes and Adjustment for Misclassification in Predictive Biomarkers
2024-8-29
Remembering Gregory Campbell (1949-2023): An Accomplished Leader, Mentor, and Biostatistical Innovator
2024-8-22
Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic
2024-8-21
Bayesian shrinkage estimation of credible subgroups for count data with excess zeros
2024-8-5
Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials
2024-8-5
Statistics Post-Pandemic: Paving the Scientific Path to Treatments, Vaccines, and Diagnostics—Special Issue for the 2022 Regulatory-Industry Statistics Workshop
2024-7-2
MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials
2024-6-26
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials
2024-6-26
A statistical method for protocol modifications with heterogeneous population variances
2024-6-26
Possible data-generating models of longitudinal continuous outcomes and intercurrent events to investigate estimands
2024-6-26
Establishing and using threshold of surrogate endpoint in relation to clinical endpoint <sup>#</sup>
2024-6-21
Eliciting the discount parameter in a power prior method on the basis of the type I error consideration
2024-6-17
Unsupervised Imputation of Non-ignorably Missing Data Using Importance-Weighted Autoencoders
2024-6-17
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs
2024-6-11
Monitoring overall survival in pivotal trials in indolent cancers
2024-6-10
Trial Design with Win Statistics for Multiple Time-to-Event Endpoints with Hierarchy
2024-6-6
Beyond the classical type I error: Bayesian metrics for Bayesian designs using informative priors
2024-4-30
Bayesian optimal designs for multi-arm multi-stage phase II randomized clinical trials with multiple endpoints
2024-4-23
Some Group Sequential Trials from Industry over the Last 30 Years
2024-3-26
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective
2024-3-25
Restricted time win ratio: from estimands to estimation
2024-3-20
Joint TITE-CRM: A Design for Dose Finding Studies for Therapies with Late-Onset Safety and Activity Outcomes
2024-3-20
Monitoring Ongoing Clinical Trials Under Fractional Brownian Motion With Drift
2024-3-8
An Instrumental Variable Approach to Learning the Causal Exposure–Response Relationship in a Randomized Dose Comparison Trial
2024-3-6
Implementation of Statistical Innovation in a Pharmaceutical Company
2024-3-5
Optimizing Patient Recruitment in Global Clinical Trials using Nature-Inspired Metaheuristics
2024-2-6
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
2024-2-5
Dose Optimization for Novel Oncology Agents: Design Options and Strategies
2024-1-23
A Two-Stage Covariate-Adjusted Response-Adaptive Enrichment Design
2024-1-23
Weighted Hazard Ratio Estimation for Delayed and Diminishing Treatment Effect
2024-1-5
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction
2024-1-5
Effects of Allocation Method and Time Trends on Identification of the Best Arm in Multi-Arm Trials
2024-1-2
Statistics in Biopharmaceutical Research 2023 Associate Editors
2024-1-2
Estimands in Oncology Early Clinical Development: Assessing the Impact of Intercurrent Events on the Dose-Toxicity Relationship
2023-12-18
Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation
2023-12-12
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing
2023-12-12
Treatment Comparisons in Adaptive Platform Trials Adjusting for Temporal Drift
2023-12-11
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials
2023-12-7
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction
2023-11-30
Adjusting for Time-Varying Treatment Switches in Randomized Clinical Trials: The Danger of Extrapolation and How to Address It
2023-11-29
Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes
2023-11-28
Correction
2023-11-2
A Method for Ensuring a Consistent Dose–Response Relationship Between An Entire Population and One Region in Multiregional Dose–Response Studies Using MCP-Mod
2023-10-31
Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions
2023-10-18
A Randomization-Based Theory for Preliminary Testing of Covariate Balance in Controlled Trials
2023-10-13
Covariate-Adaptive Biased Coin Randomization for Master Protocols with Multiple Interventions and Biomarker-Stratified Allocation
2023-10-9
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远